Phase 3 in Sight: Clearside Biomedical files for a $58 million IPO

Phase 3 in Sight: Clearside Biomedical files for a $58 million IPO

(Renaissance Capital's research analysts ) Clearside Biomedical, which is developing drugs and proprietary microinjector to combat diseases causing blindness, filed on Friday with the SEC to raise up to $58 million in an initial public offering. 

The Alpharetta, GA-based company, which was founded in 2011, plans to list on the Nasdaq under the symbol CLSD. Clearside Biomedical filed confidentially on 6/24/2014. RBC Capital Markets and Stifel are the joint bookrunners on the deal. No pricing terms were disclosed.

Share on Google Plus

About Jessica Hornberger

This is a short description in the author block about the author. You edit it by entering text in the "Biographical Info" field in the user admin panel.